Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal

Not Recruiting

Trial ID: NCT00661674


Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects--such as agitation and nausea--if opioid medications are suddenly stopped. We are interested in knowing if a medication named Ondansetron can help ease or prevent symptoms associated with opioid withdrawal. We are also interested in knowing if a similar (but more potent FDA-approved drug, palonosetron) can more effectively treat withdrawal symptoms with or without combination with an antihistamine called hydroxyzine (vistaril).

Official Title

Examination of Palonosetron and Hydroxyzine Pre-treatment as a Possible Method to Reduce the Objective Signs of Experimentally-induced Acute Opioid Withdrawal in Humans: a Double-blind, Randomized, Placebo-controlled Crossover Study

Stanford Investigator(s)

Lawrence Chu, MD, MS
Lawrence Chu, MD, MS

Professor of Anesthesiology, Perioperative and Pain Medicine


Inclusion Criteria:

   - Healthy males

   - Ages 18-35

   - No allergies to morphine or palonosetron

   - No history of addiction or substance abuse

Exclusion Criteria:

   - Female

   - Younger than 18 or older than 35

   - History of substance abuse

   - Raynaud's disease or coronary artery disease

   - Allergies to morphine or palonosetron


drug: palonosetron

drug: hydroxyzine

other: Placebo

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305